On Medication: What Residential Homes Owe to Young People About What They're Given and Why

Looked-after children are prescribed psychotropic medication — drugs that act on the mind, including antidepressants, antipsychotics, mood stabilisers, stimulants, and anxiolytics — at substantially higher rates than children in the general population. The evidence for this has accumulated over more than a decade from research in the United Kingdom and internationally, and the disparity is not marginal. Studies have consistently found that children in care are two to four times more likely to be prescribed psychotropic drugs than their peers outside the care system. The reasons for this are not straightforward: children who come into care carry, on average, significantly heavier burdens of adversity, trauma, and mental health difficulty than children who do not. Higher prevalence of genuine psychiatric need is part of the explanation. But there is a strong body of evidence and professional concern suggesting that it is not the whole explanation — that some part of the prescription rate reflects a system responding to the sequelae of trauma and disadvantage with pharmacological intervention rather than the relational and therapeutic support those children actually need. The residential sector sits at the intersection of these two possibilities, caring for children whose prescribed medication it administers daily, and bearing a responsibility for how that medication is understood and handled that the sector has not always fully grasped.

Many of the presentations that lead to psychotropic prescribing in looked-after children are ones that sit uneasily between diagnosis and description. A young person who is hyperactive, inattentive, oppositional, or dysregulated may attract a diagnosis of ADHD, conduct disorder, or an emerging personality disorder, and may be prescribed accordingly. What those behavioural presentations often reflect, however — particularly in children who have experienced significant early neglect, abuse, or disrupted attachment — is the neurobiological and psychological impact of developmental trauma. The symptoms overlap substantially. A child with disorganised attachment and complex developmental trauma can look, from a symptom checklist, indistinguishable from a child with a primary attention deficit. A young person who is chronically hypervigilant and emotionally reactive because their early caregiving environment required that of them can present in ways that invite diagnoses of mood disorder, borderline features, or oppositional defiance. This does not mean that diagnostic categories are always wrong, or that medication never helps — for some young people it clearly does, and there are children in residential care for whom a diagnosis of ADHD or bipolar disorder is accurate and for whom the right medication makes a genuine difference. But it does mean that the diagnostic pathway deserves careful scrutiny, and that prescribing on the basis of cross-sectional symptom presentation without thorough consideration of trauma history and developmental context carries real risks of pathologising adaptation rather than treating illness.

The legal framework around consent for medical treatment for children in care is one of the more complicated corners of child law, and it has direct implications for how residential homes manage medication. For children under sixteen, consent for medical treatment is ordinarily given by whoever holds parental responsibility — which, for looked-after children, is typically shared between the local authority and the child's parents, depending on the legal basis for the placement. For children who are Gillick competent — who have sufficient understanding and intelligence to understand what is proposed — their own consent is valid regardless of their age. In practice, the application of these principles to ongoing psychotropic prescribing is often less careful than it should be. Young people in residential care are sometimes taking medication whose purpose has not been adequately explained to them, whose side effects they have not been told about, and whose continued prescription has not been reviewed with their participation in any meaningful sense. This is not a minor procedural matter. It is a question of whether children are being treated as participants in decisions about their own bodies and minds, or as subjects of a management regime. A residential home that administers medication without ensuring the young person understands what it is and why they are taking it is failing that young person, regardless of whether the medication itself is clinically appropriate.

Among the most contested practices in the field is the use of PRN — pro re nata, meaning as-needed — psychotropic medication, particularly antipsychotics prescribed to be administered in response to acute agitation or behavioural disturbance. The concern is straightforward and serious: a medication given in response to behaviour, at the discretion of staff rather than on a fixed schedule, bears more than a passing resemblance to chemical restraint. The Restraint Reduction Network, NHS England's guidance on restrictive practices, and a series of CQC inspections have all flagged the misuse of PRN psychotropics as a significant concern in inpatient settings, and there is growing attention to the same issue in residential care. Where PRN medication is prescribed for a young person, the questions that need honest answers are: prescribed by whom, for what specific indication, following what assessment, and with what monitoring? If the answer to any of those questions is unclear, the prescribing itself should be scrutinised. A care home that reaches for PRN medication in the first instance when a young person is distressed, rather than as a last resort when other de-escalation approaches have genuinely been exhausted, is not using medication clinically. It is using it as a management tool, and that is both ethically problematic and, if the young person has not meaningfully consented, potentially unlawful.

The administration of medication is, on the surface, a procedural task: the right drug, the right dose, the right person, the right time, recorded accurately. Every residential home that administers medication should have policies in place covering this, and Ofsted inspectors will expect to see evidence that those policies are followed. But the residential home's responsibility in relation to medication goes considerably further than the administration itself, and the gap between the procedural and the substantive is where much of the real work lies. A home is in a unique position to observe how a young person responds to their medication over time — whether they seem sedated or flat, whether they are gaining weight, whether they are complaining of physical symptoms, whether they are asking to stop taking it, whether their sleep has changed. These are clinical observations of real significance, and they often will not reach a prescriber unless someone in the residential home ensures they do. The home is not a clinical setting, and residential workers are not prescribers, but they are the adults closest to the young person's daily life, and what they observe and report has the potential to affect clinical decisions in ways that quarterly CAMHS appointments or annual medication reviews cannot. Homes that understand this and act on it are making a genuine contribution to good clinical care. Homes that treat medication as a handover item are not.

It is not reasonable to expect residential workers to have clinical training in psychopharmacology. It is reasonable to expect them to know, for any medication they administer daily, what it is for, what the common side effects are, and what to look out for in terms of adverse reactions or signs that the medication may not be working as intended. This is a basic condition of safe practice, and in many residential homes it is not reliably met. Staff who are administering antipsychotics without knowing what antipsychotics do, who are giving stimulant medication to a young person with no idea what dysphoric side effects look like, who have no way of distinguishing a child who is calm because they are settled from a child who is blunted because they are overmedicated — those staff cannot perform even the basic observational function that the home's proximity to the young person should allow. Training in medication administration is a regulatory requirement. Training in what the medications actually are and how they act on the brain is not, and the gap between the two is a real risk. The sector has generally not invested in this area with the seriousness it deserves, and the consequence is residential homes that administer significant psychotropic regimes without the knowledge to flag concerns that a more informed workforce would routinely identify.

The most uncomfortable question the sector has to ask about psychotropic prescribing is whether, in some cases, medication is being used to manage the symptoms of inadequate care rather than to treat a genuine clinical condition. The relationship is not always easy to see, and it would be wrong to suggest it is simple or common. But there is a pattern that practitioners in the sector will recognise: a young person whose distress and dysregulation increases following a placement move, a reduction in consistent staffing, or a deterioration in their therapeutic relationships; a referral to a psychiatrist at that point; a new or increased prescription; a young person who is now more manageable but whose underlying needs remain unaddressed. Medication can reduce the legibility of a young person's distress in ways that make the system feel it has responded when it has, in a meaningful sense, only quietened the signal. This is not to say that clinicians prescribe irresponsibly, or that the homes and placing authorities who refer young people for psychiatric assessment do so in bad faith. It is to say that the circumstances of a young person's care — the quality of their relationships, the stability of their placement, the adequacy of what is on offer — are part of the clinical picture, and that prescribers who do not have that information are working with an incomplete account of the young person's situation. Residential homes that are honest about this, that provide prescribers with full context including what has changed in the young person's life and care, are doing something important.

For young people who have been prescribed psychotropic medication through childhood and adolescence, the implications extend well beyond the immediate clinical question. Being medicated during the period in which identity, self-understanding, and the capacity for emotional regulation are being formed shapes how a young person comes to understand themselves. A child who has been told, implicitly or explicitly, that they need medication to manage their mind, and who has spent years in a medicated state, may reach adulthood with a self-concept built around that framing — a sense that they are constitutionally broken in a way that requires pharmaceutical correction, rather than a person whose experiences have shaped their responses in understandable ways that therapy, relationship, and time can address. This is not an argument against medication for young people who genuinely need it. It is an argument for ensuring that the framing within which medication is given is not one that diminishes the young person's sense of their own agency and capacity. How a residential home talks about a young person's medication — whether it treats it as a settled administrative fact or as part of an ongoing conversation about the person's needs and history — contributes to that framing in ways that compound over time.

Good practice around medication in residential care is not primarily about procedures, though procedures matter. It is about culture: a culture in which the home treats medication as a clinical matter requiring ongoing attention rather than a background administrative fact, in which staff know what they are administering and why, in which young people are supported to understand their own treatment and to raise questions about it, and in which the home is prepared to raise concerns with prescribers when something does not seem right. Concretely, this means ensuring that medication reviews happen on a regular schedule and that the young person's views are genuinely sought and recorded before them. It means that when a placement move occurs, medication history and current prescribing information travel with the young person rather than being reconstructed from scratch by a new GP. It means that staff can identify and report signs of over-sedation, adverse effects, and non-therapeutic use of PRN. It means that the home is honest with commissioning authorities and clinicians about whether the young person's current environment is adequate to their needs — not relying on medication to paper over a gap that relational care should be filling. These are not heroic requirements. They are the baseline conditions under which it is responsible to administer powerful drugs to children whose capacity to advocate for themselves is, by definition, limited. The residential sector has a long way to travel before these conditions are reliably in place.